Home Antibody Technology Platforms

Background

We apply our understanding of disease biology, immune-mediated mechanisms and next generation antibody technologies to design specifically targeted antibody-based product candidates based on our DART and Fc Optimization platforms. Through these platforms we have designed antibody-based product candidates that have the potential to improve on standard treatments by having one or more of the following attributes:

  • multiple specificities;
  • increased abilities to interact with the body’s immune system to fight tumors;
  • capacity to bind more avidly to antigen targets;
  • increased potency;
  • reduced immunogenicity or
  • the ability to target cancer cells that are resistant to standard treatments.

Moreover, these technology platforms are complementary and can be combined.

Our technology platforms include:

DART® and TRIDENT™ Multi-Specific Platforms

Learn More: DART and TRIDENT Platforms

Fc Optimization Platform

Learn More: Fc Optimization Platform

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close